Randomized, dose-ranging phase II trial of nivolumab for metastatic renal cell carcinoma (mRCC)
R. Motzer
Randomized, dose-ranging phase II trial of nivolumab for metastatic renal cell carcinoma (mRCC)
R. Motzer
GENITOURINARY TUMOURS, NON PROSTATE IMMUNOTHERAPY